Abbott Laboratories (ABT) Short term Debt (2009 - 2026)

Abbott Laboratories has disclosed Short term Debt across 18 years of filings, most recently posting $3.0 billion for Q2 2026.

• In Q2 2026, Short term Debt rose 492.7% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $3.0 billion (up 492.7% YoY), while the FY2025 annual figure was $3.0 billion, up 102.2% from the prior year.
• Short term Debt came in at $3.0 billion for Q2 2026 at Abbott Laboratories, down from $4.4 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.4 billion in Q1 2026 to a low of $4.0 million in Q1 2022.
• Average Short term Debt over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2024.
• Year-over-year, Short term Debt tumbled 99.47% in 2022 and surged 57025.0% in 2023.
• Over 5 years, Short term Debt stood at $2.3 billion in 2022, then sank by 52.02% to $1.1 billion in 2023, then soared by 38.89% to $1.5 billion in 2024, then surged by 102.2% to $3.0 billion in 2025, then dropped by 0.92% to $3.0 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $3.0 billion in Q2 2026, $4.4 billion in Q1 2026, and $3.0 billion in Q4 2025.